Oculis Holding AG (OCS)
(Delayed Data from NSDQ)
$11.68 USD
-0.04 (-0.34%)
Updated Jul 22, 2024 02:59 PM ET
After-Market: $11.70 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OCS 11.68 -0.04(-0.34%)
Will OCS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCS
How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%
What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing'
OCS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect?
Other News for OCS
Oculis and EURETINA Announces the Ramin Tadayoni Award
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Oculis price target lowered by $1 at BofA, here's why
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Akero Therapeutics (AKRO)
Oculis price target raised by $2 at H.C. Wainwright, here's why